For its third fiscal quarter (ending September 30), ANI Pharmaceuticals Inc (NASDAQ: ANIP) has reported E.P.S. of $0.46 compared to $-0.55 a year ago. Relative to the consensus estimate of $0.84, this was a shortfall of $-0.38. E.P.S. were $0.56 for the latest four quarters through September 30 versus $-4.48 for the same period a year ago.
Recent Price Action
ANI Pharmaceuticals Inc (NASDAQ: ANIP) stock closed at $54.32 on 11/8/23 after a major decline of -14.6%. The stock has declined -12.0% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
ANIP is expected to continue to be an important Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
ANI Pharmaceuticals has a current Value Trend Rating of B (Positive). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. ANI Pharmaceuticals has a slightly negative Appreciation Score of 34 but a very high Power Rating of 93, triggering the Positive Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment